Medical Emergency- Cardiac Arrest and Basic Life Support (BLS)!

MEDICAL EMERGENCY- CARDIAC ARREST AND BASIC LIFE SUPPORT

Definition:

"Cardiac Arrest is a medical emergency requiring a systematic approach".

Early recognition must be followed by prompt, effective application of Basic Life Support (BLS) techniques to sustain the patient until Advanced Life Support (ALS) capabilities are available.

Management:

The management of Cardiac Arrest is a 4-step approach:

Recognition and Assessment
BLS
Advanced Cardiovascular Life Support (ACLS)
Post-resuscitation Care

1. RECOGNITION AND ASSESMENT

Verify that the respiration and circulation have ceased:

Loss of consciousness
Loss of functional ventilation (respiratory arrest or inadequate respiratory effort)
Loss of functional perfusion (No pulse).

2. BASIC LIFE SUUPORT (BLS)

The goal in cardiac arrest is the restoration of spontaneous circulation (ROSC).
The first step towards achieving this ROSC goal is prompt initiation of BLS, where the goal is to rapidly and effectively perfuse the tissues with oxygenated blood. A delay in initiating BLS or providing ineffective BLS can result in Irreversible hypoxic (not enough oxygen to the tissues) brain injury.

Summon help and resuscitation equipment.
Establish adequate airway.
Provide rescue breathing by delivering two slow, deep breaths. Ventilate by mouth-to mouth, mouth-to mask, or bag-valve-mask techniques.
Check for pulse and other signs of circulation. When available, assess heart rhythm with an automated external defibrillator or Monophasic/Biphasic defibrillator.

If ventricular tachycardia or ventricular fibrillation are documented, defibrillate with 200 joules of direct current shock.
If the first shock fails to terminate the dysrhythmia, a second shock with 200-300 joules should be attempted. if the first two shocks fail, shock again with 360 Joules.

5. Reassess cardiac rhythm and check for a pulse. If no pulse or other signs of circulation are present, initiate rescue breathing and Chest compressions.

For Rescue breathing:

Give each breathing slowly over 2 seconds.

Deliver 1-12 breaths per minute or 1 breath every 4-5 seconds.

For External Chest compression:

Position patient supine on a firm surface.

Ensure proper placement of your hands on sternum.

Depress sternum at a rate of 80-100 cycles per minute (50% of cycle should be compression).

For every 15 chest compressions, give 2 breaths.

Comments

Diabetes Mellitus: Types!

TYPES OF DIABETES MELLITUS 1. TYPE1 DM Type 1 DM is usually diagnosed before age 30 years, but it can develop at any age. T1DM is an autoimmune disease in which insulin producing B-cells are destroyed. The presence of Human Leucocyte Antigens (HLAs ) is associated with the development of T1DM. In addition, these individuals often develop Islet cell antibodies , Insulin Autoantibodies or Glutamic Acid decarboxylase autoantibodies . At the time of development of diagnosis of T1DM, it is usually believed that most of the patients have 80-90%loss of beta cells. The remaining beta cells function at the diagnosis creates a " HONEYMOON PERIOD" during which the blood glucose levels are easier to control, and smaller amounts of insulin are required. after this, the remaining beta cells function is completely lost, and the patients become completely deficient of insulin and hence require exogenous insulin. 2. TYPE1.5 DM: Also referred as Latent autoimmune diabetes in Adults (LAD)

Diabetes Mellitus: Pharmacotherapy- Gliptins and a-Glycoside Inhibitors!

PHARMACOTHERAPY: Medications classifications include: Sulfonyl Urea's Nonsylfonylurea Secretagogues (a-Glinides) Biguanides Thiazolidinediones a-Glucosidase Inhibitors Dipeptidyl Peptidase-4 Inhibitors (Gliptins) Sodium-glucose co-transporter (SGLT) Inhibitors Central-Acting Dopamine Agonists Bile Acid Sequestrants Insulin therapy 5. a-GLUCOSIDASE INHIBITORS Acarbose and Miglitol are a-glucosidase inhibitors currently approved in the United States. Mechanism of Action: An enzyme that is along the brush border of the intestine cells called a-glucosidase; breaks down the complex carbohydrates into simple sugars, resulting in absorption. The a-glucosidase inhibitors work by delaying the absorption of carbohydrates from the intestinal tract, which reduces the rise in postprandial glucose levels. Therapy: As a monotherapy , a-glucosidase inhibitors primarily reduce post-prandial glucose excursions. Clinical Use: FPG concentrations have been decreased by 40-50mg/dL and A1c level

GASTRO-ESOPHAGEAL REFLUX DISEASE (GERD)!

MANAGEMENT OF GASTRO-ESOPHAGEAL REFLUX DISEASE "GERD refers to the endoscopically determined esophagitis or endoscopy-negative reflux disease" . "GERD is the term used to describe any symptomatic clinical condition or histopathological alteration resulting from episodes of reflux of acid, pepsin and occasionally, bile into the esophagus from the stomach". Patients with uninvestigated "reflux-like" symptoms should be managed as patients with uninvestigated dyspepsia. There is currently no evidence that H.pylori should be investigated in patients with GERD. Symptoms: Heartburn is the characteristic symptom of GERD. Acid regurgitation Dysphagia Belching Upper abdominal discomfort Bloating and postprandial fullness Chest pain Hoarseness Cough Complications include: Esophageal ulceration Formation of specialized columnar-lined esophagus at the gastro-esophageal junction known as Barretts Esophagus . Mechanism of Acid Reflux: The mechanism of acid reflux is mu

Medical Concepts

Search This Blog